| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3568 | 2019 |
| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial WTA Van Der Graaf, JY Blay, SP Chawla, DW Kim, B Bui-Nguyen, ... The Lancet 379 (9829), 1879-1886, 2012 | 2320 | 2012 |
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised … GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ... The Lancet 381 (9863), 295-302, 2013 | 1570 | 2013 |
| Cabozantinib in progressive medullary thyroid cancer R Elisei, MJ Schlumberger, SP Müller, P Schöffski, MS Brose, MH Shah, ... Journal of clinical oncology 31 (29), 3639-3646, 2013 | 1304 | 2013 |
| Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... The lancet oncology 15 (4), 415-423, 2014 | 1088 | 2014 |
| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer E Van Cutsem, H Van De Velde, P Karasek, H Oettle, WL Vervenne, ... Journal of clinical oncology 22 (8), 1430-1438, 2004 | 1010 | 2004 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67, 2018 | 936 | 2018 |
| Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127-137, 2022 | 900 | 2022 |
| Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ... The Lancet 387 (10028), 1629-1637, 2016 | 830 | 2016 |
| Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for … S Sleijfer, I Ray-Coquard, Z Papai, A Le Cesne, M Scurr, P Schöffski, ... Journal of clinical oncology 27 (19), 3126-3132, 2009 | 791 | 2009 |
| XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Cassidy, J Tabernero, C Twelves, R Brunet, C Butts, T Conroy, ... Journal of Clinical Oncology 22 (11), 2084-2091, 2004 | 743 | 2004 |
| Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ... The lancet oncology 10 (8), 757-763, 2009 | 723 | 2009 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ... Annals of Oncology 32 (11), 1348-1365, 2021 | 697 | 2021 |
| Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv68-iv78, 2018 | 630 | 2018 |
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ... The Lancet Oncology 19 (1), 51-64, 2018 | 629 | 2018 |
| Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 596 | 2018 |
| Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients CH Köhne, D Cunningham, F Di Costanzo, B Glimelius, G Blijham, ... Annals of Oncology 13 (2), 308-317, 2002 | 577 | 2002 |
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial DC Smith, MR Smith, C Sweeney, AA Elfiky, C Logothetis, PG Corn, ... Journal of clinical oncology 31 (4), 412-419, 2013 | 533 | 2013 |
| Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer MM Borner, P Schöffski, R De Wit, F Caponigro, G Comella, A Sulkes, ... European Journal of Cancer 38 (3), 349-358, 2002 | 401 | 2002 |
| Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, ... Annals of oncology 33 (1), 20-33, 2022 | 383 | 2022 |
